Lotus Eye H1 PBT rises 95% as costs trail revenue growth
Key highlights
- Lotus Eye reported H1 FY27 revenue from operations of Rs 34.78 crore, up 30.97% year on year.
- Lotus Eye's H1 FY27 PBT rose 95.43% to Rs 1.57 crore from Rs 80.28 lakh.
- H1 FY27 total expenses were Rs 33.72 crore, up 28.62% from H1 FY26.
- Lotus Eye reported Q2 FY27 revenue of Rs 17.72 crore, up 35.94% year on year.
powered by IRIS

Lotus Eye Hospital and Institute Limited reported first-half (H1) FY27 revenue from operations of Rs 34.78 crore for the six months ended September 30, 2026, up 30.97% year on year, while profit before tax rose 95.43% to Rs 1.57 crore as expenses increased 28.62%.
Know Lotus Eye Hospital & Institute inside out
Results, valuation, peers and who's buying, in one view.
What did Lotus Eye report for H1 FY27?
Lotus Eye reported Rs 34.78 crore of revenue from operations in H1 FY27, a 30.97% increase from H1 FY26. Profit before tax (PBT) reached Rs 1.57 crore, compared with Rs 80.28 lakh a year earlier, while net profit rose 59.44% to Rs 1.05 crore. The H1 period covered the six months ended September 30, 2026.
The difference between revenue and profit growth was substantial. Revenue increased by 30.97%, whereas PBT increased by 95.43%, a gap of 64.46 percentage points. Net profit growth of 59.44% was below the PBT increase, but remained above the revenue growth rate for the half year.
Lotus Eye said its unaudited quarterly and half-yearly results for the period ended September 30, 2026 were reviewed by the Audit Committee and approved by the Board on November 11, 2026. The statutory auditors conducted a limited review, rather than the presentation describing a full audit of the interim results.
Why did Lotus Eye's PBT grow faster than revenue?
Lotus Eye's reported expense growth of 28.62% was lower than its 30.97% revenue-from-operations growth in H1 FY27. Total expenses were Rs 33.72 crore, meaning expenses grew 2.35 percentage points more slowly than revenue. That reported gap coincided with the 95.43% increase in PBT to Rs 1.57 crore.
The presentation identifies employee benefits, service expenses, materials consumed, other expenses, depreciation and finance costs in its H1 FY27 operating-cost structure. It does not provide numerical values or growth rates for those individual categories. As a result, the supplied disclosure does not identify which expense line contributed most to the lower overall expense-growth rate.
The presentation also does not disclose a tax expense, effective tax rate or specific tax adjustment for H1 FY27. Therefore, it does not explain why net profit growth of 59.44% to Rs 1.05 crore was lower than the 95.43% rise in PBT. The disclosed result supports a comparison of revenue and total expenses, but not a conclusion about pricing, patient volumes, procedure mix or individual cost controls.
How did Lotus Eye's Q2 FY27 performance compare with last year?
Lotus Eye reported second-quarter (Q2) FY27 revenue of Rs 17.72 crore, up 35.94% year on year. This was 4.97 percentage points higher than the 30.97% revenue growth reported for H1 FY27. Q2 PBT was Rs 55.87 lakh, compared with Rs 7.30 lakh in Q2 FY26.
Q2 FY27 net profit was Rs 43.95 lakh, compared with Rs 11.58 lakh in Q2 FY26. The presentation therefore records increases in both pre-tax and after-tax earnings in the quarter ended September 30, 2026. It does not state the percentage change in Q2 PBT or net profit, although it provides the amounts for both periods.
The Q2 results formed part of H1 FY27 PBT of Rs 1.57 crore and H1 net profit of Rs 1.05 crore. Lotus Eye does not provide a separate Q1 income statement, outpatient count, surgical-procedure volume or monthly revenue trend in the supplied pages. The available figures show that Q2 revenue growth exceeded the first-half rate, but do not establish the operating driver of that change.
Got a follow-up? Ask IRIS
What business does Lotus Eye operate and what is its financial position?
Lotus Eye reports one operating segment under Indian Accounting Standard (Ind AS) 108: eye-care related sales and services. Its stated clinical offerings include cataract and LASIK, retina, glaucoma, cornea, pediatric ophthalmology, diabetic retinopathy, squint, oculoplasty and optical services. The company is headquartered in Coimbatore and has operations across Tamil Nadu and Kerala.
As at September 30, 2026, Lotus Eye reported total assets of Rs 100.59 crore and total equity of Rs 61.21 crore. Total borrowings were Rs 17.73 crore, while cash equivalents were Rs 1.74 crore. The company specifies that borrowings include current and non-current borrowings but exclude lease liabilities.
Lotus Eye had 2,07,96,330 equity shares with a face value of Rs 10 each as at September 30, 2026. Promoters and the promoter group held 40.14%, while public shareholders held 59.86%. Although the presentation includes a balance-sheet chart for March 31, 2026 and September 30, 2026, its text does not state the earlier-period asset, equity, borrowing or cash figures.
What does the H1 FY27 cost and profit pattern show?
Lotus Eye's H1 FY27 figures show revenue rising faster than total expenses, with a 30.97% rise in revenue from operations against 28.62% expense growth. PBT consequently grew 95.43% to Rs 1.57 crore, compared with Rs 80.28 lakh in H1 FY26. This is the clearest reported comparison connecting the first-half revenue and profitability outcome.
The operating pattern should be read alongside the difference between PBT and net profit. Net profit increased 59.44% to Rs 1.05 crore, below the PBT growth rate, but Lotus Eye has not provided tax-line detail to explain the difference. Likewise, the cost chart identifies six broad cost categories but does not disclose their individual H1 FY27 values.
The presentation is limited to reported financial and balance-sheet metrics rather than management guidance. It gives no revenue target, procedure target, cost target or expansion timetable for the remainder of FY27. It therefore provides a baseline for comparing subsequent revenue, expense and PBT trends, rather than a forecast of those measures.
Conclusion
Lotus Eye recorded a faster increase in H1 FY27 PBT than in revenue because total expenses grew 28.62%, below the 30.97% increase in revenue from operations. The company reported Rs 34.78 crore of H1 revenue, Rs 1.57 crore of PBT and Rs 1.05 crore of net profit for the six months ended September 30, 2026.
The next results will indicate whether Q2 FY27 revenue growth of 35.94% and the gap between revenue and expense growth continue. Lotus Eye has disclosed no FY27 revenue or cost target, no expansion schedule and no procedure-volume target, while its September 30 balance-sheet baseline includes Rs 17.73 crore of borrowings and Rs 1.74 crore of cash equivalents.


